Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis.
Journal
Obesity (Silver Spring, Md.)
ISSN: 1930-739X
Titre abrégé: Obesity (Silver Spring)
Pays: United States
ID NLM: 101264860
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
05
02
2019
accepted:
22
07
2019
pubmed:
28
10
2019
medline:
28
4
2020
entrez:
29
10
2019
Statut:
ppublish
Résumé
Bile acids (BAs) are important molecules in the progression of nonalcoholic fatty liver disease. This study aimed to investigate BA profile alterations in Chinese nonalcoholic steatohepatitis (NASH) patients. BA profiles in serum and liver tissues were determined by ultraperformance liquid chromatography coupled to tandem mass spectrometry in patients from two different clinical centers. A total of 134 participants were enrolled in this study to serve as the training (n = 87) and validation (n = 47) cohorts. The ratio of circulating conjugated chenodeoxycholic acids to muricholic acids (P = 0.001) was elevated from healthy controls to non-NASH individuals to NASH individuals in a stepwise manner in the training cohort and was positively associated with the histological severity of NASH: steatosis (R Altered BA profile in NASH is closely associated with the severity of liver lesions, and it has the potential for predicting NASH development.
Substances chimiques
Bile Acids and Salts
0
Cholic Acids
0
Chenodeoxycholic Acid
0GEI24LG0J
muricholic acid
39016-49-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2055-2066Informations de copyright
© 2019 The Obesity Society.
Références
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
Wong VWS, Chan WK, Chitturi S, et al. Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol 2017;33:70-85.
Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017;377:2063-2072.
Harrison SA. NASH, from diagnosis to treatment: where do we stand? Hepatology 2016;62:1652-1655.
Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2017;25:1054.
Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63:764-765.
Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 2016;24:41-50.
Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 2016;13:412-425.
Gustafsson BE, Bo A, Björkhem I, Einarsson K, Gustafsson JA. Effects of feeding chenodeoxycholic acid on metabolism of cholesterol and bile acids in germ-free rats. Lipids 1981;16:228-233.
Jiao N, Baker SS, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut 2018;67:188-1891.
Puri P, Daita K, Joyce A, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 2018;67:534-548.
Legry V, Francque S, Haas JT, et al. Bile acid alterations are associated with insulin resistance, but not with NASH in obese subjects. J Clin Endocr Metab 2017;102:3783-3794.
Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 2016;7:22-39.
Neuschwandertetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-965.
Roth JD, Feigh M, Veidal SS, et al. INT-767 improves histopathological features in a diet-inducedob/obmouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol 2018;24:195-210.
Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015;6:10166. doi:10.1038/ncomms10166
McGettigan BM, McMahan RH, Luo Y, et al. Sevelamer improves steatohepatitis, inhibits liver and intestinal farnesoid x receptor (FXR), and reverses innate immune dysregulation in a mouse model of non-alcoholic fatty liver disease. J Biol Chem 2016;291:23058-23067.
Kleiner DE, Brunt EM, Natta MLV, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
Sanyal AJ, Chalasani N, Kowdley KV, et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685.
Zhou K, Wang J, Xie G, et al. Distinct plasma bile acid profiles of biliary atresia and neonatal hepatitis syndrome. J Proteome Res 2015;14:4844-4850.
Xie G, Wang Y, Wang X, et al. Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS. J Proteome Res 2015;14:850-859.
Xiang X, Backman JT, Neuvonen PJ, Niemi M. Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings. Basic Clin Pharmacol Toxicol 2012;110:245-252.
Ferslew BC, Xie G, Johnston CK, et al. Altered bile acid metabolome in patients with non-alcoholic steatohepatitis. Dig Dis Sci 2015;60:3318-3328.
Mouzaki M, Wang AY, Bandsma R, et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS One 2016;11:e151829. doi:10.1371/journal.pone.0151829
Lake AD, Novak P, Shipkova P, et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol 2013;268:132-140.
Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov 2016;15:249-274.
Takahashi S, Fukami T, Masuo Y, et al. Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. J Lipid Res 2016;57:2130-2137.
Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003;72:137-174.
Nakashima T, Sakamoto Y, Inaba K, et al. A paucity of unusual trihydroxy bile acids in the urine of patients with severe liver diseases. Hepatology 1999;29:1518-1522.
Gao J, Xu B, Zhang X, et al. Association between serum bile acid profiles and gestational diabetes mellitus: a targeted metabolomics study. Clin Chim Acta 2016;459:63-72.
Zöhrer E, Meinel K, Fauler G, et al. Neonatal sepsis leads to early rise of rare serum bile acid tauro-omega-muricholic acid (TOMCA). Pediatr Res 2018;84:66-70.
Nakashima T, Sano A, Seto Y, et al. Unusual trihydroxy bile acids in the urine of healthy humans. Clin Chim Acta 1986;160:47-53.
Deo AK, Bandiera SM. Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid. Drug Metab Dispos 2008;36:1983-1991.
Ferrell JM, Boehme S, Li F, Chiang JYL. Cholesterol 7α-hydroxylase-deficient mice are protected from high-fat/high-cholesterol diet-induced metabolic disorders. J Lipid Res 2016;57:1144-1154.
Tiangang L, Michelle M, Shannon B, et al. Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology 2011;53:996-1006.
Bonde Y, Eggertsen G, Rudling M. Mice abundant in muricholic bile acids show resistance to dietary induced steatosis, weight gain, and to impaired glucose metabolism. PLoS One 2016;11:e147772. doi:10.1371/journal.pone.0147772
Hu X, Bonde Y, Eggertsen G, Rudling M. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. J Intern Med 2013;275:27-38.
Schreuder TC, Halenicek M. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010;298:G440-G445.
Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 2011;178:175-186.
Cai SY, Ouyang X, Chen Y, et al. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight 2017;2:e90780. doi:10.1172/jci.insight.90780
Fujino Y, Nakayama K, Yoshimura K, Furuya Y, Yonaga T. Suppression of hepatic HMG-CoA reductase activity by beta-muricholic acid in mice fed a diet containing cholesterol and cholic acid. Jpn J Pharmacol 1988;46:421-423.
Wang X, Xie G, Zhao A, et al. Serum bile acids are associated with pathological progression of hepatitis b-induced cirrhosis. J Proteome Res 2015;15:1126-1134.
Verbeke L, Farre R, Verbinnen B, et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol 2015;185:409-419.